DCTN2

Across TCGA pan-cancer cohorts, DCTN2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of DCTN2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where DCTN2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types DCTN2 is over-expressed in tumor, although a few such as COAD and LSCC show the opposite, repressed pattern.

COAD, LSCC, and LUAD are the cancer types where DCTN2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DCTN2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	−0.533	<.001	11	view →
LSCC	Female	II,III,IV	−0.488	<.001	9	view →
LUAD	Female	II,III,IV	−0.303	<.001	9	view →
HNSC	Male	All	−0.366	<.001	8	view →
PDAC	Female	II,III,IV	−0.349	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

DCTN2–COAD

Open the COAD breakdown →